- Price:
- $21.81
- Open:
- $21.73
- Previous close:
- $21.85
- Day's range:
- $21.73 - $22.02
- Year's range:
- $20.34 - $32.88
- Net Income per Share:
- 1.02
- Price-to-Earnings ratio:
- 21.38
- 52-week Price Range:
- $22.52
- Volume:
- $953,904.00
- Average volume:
- $1,141,709.00
Company profile for Genmab A/S
Genmab A/S is a Danish biotechnology company focused on developing therapeutic antibodies for the treatment of cancer and other diseases. It has a portfolio of over 14 antibody products, of which 7 are marketed and the remainder are in various stages of development. Its flagship product, Daratumumab, is a human monoclonal antibody used to treat multiple myeloma, non-MM blood cancers, and AL amyloidosis. The company has a number of collaboration agreements with companies such as Seagen Inc., CureVac AG, AbbVie, BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS and Bolt Biotherapeutics, Inc. for the research and development of its products.
Founded in 1999, Genmab A/S has grown steadily over the years to become a leader in the field of antibody-based therapeutics, with numerous products in development and Phase II clinical trials and more than 14 antibody products approved for commercialization. The company is headquartered in Copenhagen, Denmark and is listed on the Copenhagen Stock Exchange. It has more than 500 employees globally, with offices in USA, Canada, Australia and Europe.
Genmab A/S has pioneered several breakthroughs in the field of antibody-based therapeutics. For example, it has developed the DuoBody and HexaBody technology, which links two or more monoclonal antibodies together in order to increase their efficacy and potency. Additionally, the company has developed the Teprotumumab, which is the first approved targeted treatment therapy for thyroid eye disease.
Genmab A/S has also increased its focus on research and development in recent years, and has formed several strategic research and development partnerships with some of the world’s largest pharmaceutical companies such as AbbVie, BioNTech and Novo Nordisk. In 2019, the company registered a total of 30 patents, which is a significant increase from the previous year.
Genmab A/S has continued to position itself at the forefront of the biotechnology industry, with several of its products being approved for commercialization and several more in late-stage clinical trials. With its increasing R&D efforts and expanding presence in the global biotechnology space, the company is well-positioned to continue leading the way in antibody-based therapeutics.
- Stock exchanges:
- NASDAQ
- Sector:
- Healthcare
- Industries:
- Biotechnology
- Ticker:
- GMAB
- CIK:
- 0001434265
- ISIN:
- US3723032062
- Website:
- https://www.genmab.com
- Phone:
- 45 70 20 27 28
- Origin:
- Denmark
- Employees:
- 1,560